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Mutations in Wilms’ tumor 1 (WT1) cause a wide spectrum
of renal manifestations, eventually leading to end-stage
kidney failure. Insufficient understanding of WT1’s molecular
functions in kidney development has hampered efficient
therapeutic applications for WT1-associated diseases.
Recently, the generation and characterization of mouse
models and application of multiple state-of-the-art
approaches have significantly expanded our understanding
of the molecular mechanisms of how WT1 mutations lead to
kidney failure. Here, we discuss the WT1 binding consensus
and illustrate the major roles of WT1 in different cell
populations in kidney biology. WT1 controls metanephric
mesenchyme (MM) self-renewal and proliferation mainly by
regulating FGF and BMP-pSMAD signaling pathways as well
as Sall1 and Pax2, encoding key transcription factors; WT1
drives MM differentiation and mesenchyme–epithelial
transition by targeting Fgf8 and Wnt4; WT1 defines podocyte
identity by activation of other podocyte-specific transcription
factors, including Mafb, Lmx1b, FoxC2, and Tcf21. These
factors potentially cooperate with WT1 regulating the
expression of components and regulators of the cytoskeleton
for establishing podocyte polarity, slit diaphragm structure,
and focal adhesion to the glomerular basement membrane.
Understanding of WT1’s function in kidney biology including
WT1-regulated pathways will give insights that will
eventually help therapeutic applications.
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Kidney failure is a worldwide public health problem, with
increasing incidence and prevalence, high costs, and poor
outcomes.1 Some of those renal manifestations are caused
by Wilms’ tumor 1 (WT1) mutations, including Wilms’
tumor, the Denys-Drash syndrome (DDS), the Frasier
syndrome (FS), and the steroid-resistant nephrotic syndrome.
To understand WT1 function in kidney development and
homeostasis, multiple mouse models have been generated and
characterized. Particularly, the generation of Wt1 conditional
knockout mice crossed to inducible and cell-specific Cre mice
allowed to dissect Wt1 function with regard to specific cell
populations and the time of development. To decipher the
molecular mechanisms of Wt1 mutations leading to kidney
failure, multiple state-of-the-art experimental approaches
have been applied, such as chromatin immunoprecipitation
followed by high-throughput sequencing (ChIP-Seq) using
embryonic and adult kidneys. In this review, we present and
summarize our current understanding of WT1’s function
in kidney biology including WT1-controlled regulatory
networks. We also discuss how this knowledge might be
translated into therapeutic applications.
WT1 AND ITS EXPRESSION PATTERN IN THE MAMMALIAN
KIDNEY
The human WT1 gene spans 50 kb of genomic DNA and
comprises 10 exons, which generate a 3 kb mRNA. It encodes
a protein with an amino-terminal proline- and glutamine-rich
protein interaction domain and four carboxy-terminal
Krüppel-type (Cys2-His2) zinc fingers, major characteristics
of a typical transcription factor. Expression of WT1 is
complex, with at least 36 isoforms derived from alternative
splicing, usage of alternative translation start sites, and RNA
editing. There are two major alternative splice sites resulting
in four isoforms: proteins with or without the central 17
amino acids from alternative splicing of exon 5 and proteins
including or excluding the three amino acids lysine,
threonine, and serine (KTS) between the third and fourth
zinc finger domain (Figure 1a). The corresponding isoforms
are termed WT1+KTS and WT1−KTS and are expressed in a
constant ratio of about 2:1 in humans.2 WT1 mutations in
human patients are commonly associated with dysfunction
of the urogenital system, indicating the essential roles of
WT1 for kidney and gonad development. In mammals, the
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definitive kidney, the metanephros, forms at the end of
the posterior intermediate mesoderm through distinct con-
secutive steps.3 In brief, first, a specialized region called
metanephric mesenchyme (MM) is formed in the posterior
intermediate mesoderm; second, the MM induces an out-
growth of the nephric duct called ureteric bud (UB); third,
the UB invades the MM and induces adjacent MM cells to
condense around the UB tip, forming the cap mesenchyme;
the remaining MM cells are called stromal mesenchyme;
fourth, the cap mesenchyme cells induce UB to branch,
whereas a subset of the cap mesenchyme (pre-tubular
aggregate) on the ventral side of the UB tips undergoes
mesenchymal–epithelial transition to form a renal vesicle.
This fuses with the ureteric stalk, generating a comma-shaped
body and subsequently an S-shaped body with a proximal-
distal cleft. The most proximal cleft is infiltrated by
endothelial cells and forms the glomerular tuft. Finally,
reciprocal epithelial–mesenchymal interactions induce UB to
branch repeatedly in a highly reproducible manner, and new
nephrons form from the mesenchyme adjacent to each new
UB tip. The ureteric branches form the collecting duct tree
that connects the nephrons to the ureter and drain the urine
into the bladder. The earliest WT1 signal is detected in
intermediate mesoderm at E9.0, and then the signal increases
in cap mesenchyme after UB induction. Higher expression is
also detected in pre-tubular aggregates, proximal parts of
renal vesicle, and comma- and S-shaped body. The highest
expression is in capillary loops and finally restricted to
podocytes of the glomerulus, where expression is maintained
throughout life (Figure 1b).
WT1 ALTERATIONS AND RENAL ANOMALIES
WT1 was initially identified using a positional cloning
approach, as it is located in a genomic region, deletion of
which results in the WAGR syndrome (Wilms’ tumor,
aniridia, genitourinary anomalies, and mental retarda-
tion).4,5 Since then many WT1 mutations were identified,
including missense, nonsense, splice site mutations, as well as
deletions.6 WT1 mutations have been found to be associated
with a large spectrum of phenotypes at the clinical level,
including Wilms’ tumor, the DDS, the FS, and the isolated
steroid-resistant nephrotic syndrome, all of which progress to
end-stage kidney disease. Overall, there is a solid genotype–
phenotype association of WT1 diseases.6–8 Approximately
20% of WTs, the most commonly found kidney tumor in
children, are caused by WT1 mutations. A high number of
bilateral tumors are associated with truncation mutations,
particularly in the 5′ half of the WT1 gene. Mutations within
exon 8 or 9 of WT1 usually lead to the DDS, characterized by
diffuse mesangial sclerosis, urogenital abnormalities, and a
high risk of developing Wilms’ tumor. Disruption of the KTS
splicing, caused by splice site mutations, results in the loss of
the WT1+KTS isoform and leads to the FS, characterized
by pseudohermaphroditism and focal segmental glomerulo-
sclerosis. In addition, there are idiopathic steroid-resistant
glomerulopathies caused by mutations in WT1. Wilms’
tumors or nephroblastoma often contain metanephric
blastema, stromal and epithelial derivatives. It is therefore
thought to arise by a failure of kidney progenitor cells to
differentiate. On the other hand, glomerulopathies as seen in
DDS, FS, and steroid-resistant nephrotic syndrome are
considered to result from the loss of WT1 function during
podocyte development and maintenance. In the following, we
will discuss WT1 as a transcription factor and discriminate
between its functions in kidney progenitor cells and in
podocytes.
SEQUENCE AND LOCALIZATION OF WT1 BINDING SITES
WT1 has been suggested to recognize and bind the EGR1-like
GC-rich DNA sequence.9 However, a physiologically relevant
WT1 binding sequence cannot only be deduced from in vitro
experiments. Recently, chromatin immunoprecipitation
(ChIP) followed by microarray hybridization or high-
throughput sequencing (ChIP-seq) experiments provided
insight into the genomic DNA binding characteristics of
WT1 during kidney development and homeostasis.10–13 The
WT1 binding motif derived from ChIP followed by micro-
array hybridization shows a high similarity to the EGR1
binding motif, whereas the motif based on ChIP-seq
experiments demonstrates a slight variation in the form of
an exchange from C to A. Considering all the motifs identified
from ChIP-seq experiments, WT1 recognizes the sequence
of Gg/tGGGAGg/t.11–13 Interestingly, in many gene regulatory
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Figure 1 |Wilms’ tumor 1 (WT1) protein structure and Wt1
expression pattern in developing murine kidney. (a) Structure of
WT1 protein showing alternative splice regions consisting of 17
amino acids encoded by exon 5 and amino acids lysine, threonine,
and serine (KTS) encoded by the 3′-end of exon 9 and the different
functional domains. (b) The expression of Wt1 in developing kidney
(E15.5) detected by in-situ hybridization (picture provided by Dagmar
Kruspe). Wt1 is expressed in cap mesenchyme (CM) surrounding the
ureteric bud (UB) and at very low level in stromal mesenchyme (SM).
Wt1 expression is increased in pre-tubular aggregates (PTAs) that
begin to undergo mesenchymal to epithelial transition to form the
renal vesicle (RV). Wt1 is expressed in the proximal part of renal
vesicles and the S-shaped bodies (S), which give rise to podocyte
precursors in the capillary loop (C). The highest expression of Wt1 is
found in podocytes within glomeruli (G). Scale bar = 20 μm.
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regions, we found two similar motifs containing GGGAGg/t
close to each other, suggesting that WT1 can form and bind as
a homodimer.12 This could explain the dominant manner of
manifestation of diseases caused by WT1 mutations.
In the past, numerous potential target genes of WT1 were
identified by characterization of the promoter regions via
various approaches, such as reporter assays, electrophoretic
mobility shift assay, and co-transfection assays (Supplemen-
tary Table S1 online). Examination of genomic WT1 binding
sites in kidneys revealed that they were significantly enriched in
the promoter region near the transcription start sites. Mean-
while, combining all the WT1 peaks from ChIP-seq results
shows around 45% of WT1 binding sites localized more than
50 kb away from transcription start sites, indicating that
WT1 regulates gene expression via both proximal and distal
regulatory elements, thus highly extending the WT1 potential
target gene list.10–13 In addition, the differences of WT1
binding loci between developing and adult kidneys as well as
the different gene expression patterns between Wt1 mutant
MM and podocytes indicate that the gene sets regulated by
WT1 significantly depend on the specific cellular context.
WT1 IS INVOLVED IN SELF-RENEWAL AND DIFFERENTIATION
OF MM
In view of the important function of WT1 in kidneys, several
animal models (e.g., mouse, zebrafish, and Xenopus) have
been applied. Particularly, generation and characterization of
different mouse models have greatly elucidated the WT1
function.14 Wt1 knockout mice have no kidneys with failure
of UB outgrowth and MM degeneration by apoptosis at
E12. In Wt1−/− MM cells, a lack of FGF and enhanced
BMP-pSMAD signaling was observed. Mechanistically,
WT1 directly regulates FGF20/16 expression and activates
FGF signaling for MM survival.11 After the MM responds
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Figure 2 |Wilms’ tumor 1 (WT1) contributes to metanephric mesenchyme self-renewal and its differentiation. WT1, Sall1, Pax2, Six2, and
Hoxd11 are individually required for survival and self-renewal of metanephric mesenchyme (MM). Among them, WT1 is upstream of Sall1 and
Pax2 transcription factors. BMP4 induces the apoptosis of MM; however, BMP7 promotes the MM differentiation. In balance of the BMP-pSMAD
signaling in MM, WT1 directly regulates Bmper, a BMP-pSMAD inhibitor, and activates the FGF signaling pathway via regulating Fgf20/Fgf16 and
Gas1 expression to antagonize BMP-pSMAD signaling for the survival and self-renewal of MM. High expression level of Wnt9b beneath the
ureteric tip increases the Wnt singling activity nearing the MM; there, the β-catenin-LEF/TCF complex works together with Six2 and WT1
activating the critical differentiation factors, Fgf8 and Wnt4, to form pre-tubular aggregate (PTA). Signals produced by PTA promote the
mesenchyme–epithelial transition (MET) to form renal vesicles. The proximal part of the renal vesicle expressing Wt1 will develop into the
epithelial cells of the glomerulus and the distal part of the renal vesicle expressing Lhx1 will develop into the epithelial cells of the nephron
tubule.
Figure 3 |WT1 defines the podocyte-specific morphology. (a) Ultrastructural kidney analysis of Wt1 mutant and control adult mice treated
with doxycycline for 6 days. Podocytes (arrow) and endothelial cells (arrowheads) were abnormally distant from the GBM (G), which was itself
irregularly shaped in the mutant tissue. Black dots indicate negative charges by polyethylenimine staining. No obvious charge differences
between the GBMs of mutant and control glomeruli are detectable. Scale bar = 0.5 μm. This figure is adapted with permission from Dong
et al.12 (b) Schematic WT1-controlled networks for establishing podocyte-specific morphology. WT1 regulates the slit diaphragm complex
components, including Nephrin (Nphs1), Podocin (Nphs2), Membrane-associated guanylate kinase, WW and PDZ domain–containing protein 2
(Magi2), CD2-associated protein (CD2AP), NCK adaptor protein 2 (NCK2), Kin of IRRE-like protein 1/2/3 (Kirrel) and phospholipase C, and epsilon
1 (Plce1). WT1 controls focal adhesion by regulating Integrin α3 (Itga3), Integrin β1 (Itgb1), Laminin α5 (Lama5), and Laminin β2 (Lamb2). WT1
also controls the cytoskeleton components and its regulators to establish the podocyte polarity—namely, Synaptopodin (Synpo), α-actinin-4,
myosin, heavy polypeptide 9, non-muscle (Myh9), Rho GTPase-activating protein 24 (Arhgap24), and Atypical protein kinase C (aPKC). (c) Multiple
Wt1 binding sites to cis-regulatory regions of Synpo and Magi2 as viewed in the UCSC browser within the indicated genomic intervals.
Conservation denotes placental mammal basewise conservation by phastCons score. The peaks indicate the overlapping WT1 binding sites
generated from Kreidberg and colleagues’ and our ChIP-seq data.12,13
686 Kidney International (2015) 88, 684–690
min i rev iew L Dong et al.: Function of WT1 in kidney biology
to FGF signals, WT1-dependent GAS1 can promote MM
proliferation by activation of intracellular FGF-stimulated
AKT signaling.15 Also, WT1 directly activates the expression
of BMP modulator Bmper to repress pSMAD signaling for
permission of MM survival.11 In addition, mutation of WT1
in Wilms’ tumor is frequently accompanied by canonical Wnt
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activation.16 WT1 is indicated to inhibit Wnt signaling in the
MM by activating CXXC5 expression, encoding a Wnt/
β-catenin inhibitor.10 The interaction of BMP, FGF, and Wnt
signaling has been implicated for the survival of MM.17
Interestingly, WT1 can affect all key signaling pathways in
MM by transcriptional regulation of respective modulators.
As shown for Wt1, inactivation of other transcription factors
encoding genes like Sall1/4, Six1/2, Eya1, Pax2, and Hoxd11
also results in kidney agenesis.17 Among them, WT1 directly
regulates Sall1 and Pax2 in MM (Figure 2).10
In addition to self-renewal and expansion of nephron
progenitors, signals for initiation of nephrogenesis are
required in order for kidney development to occur. One
such signal is Wnt9b, which is expressed at a high level
beneath the ureteric tip and induces the adjacent nephron
progenitor cells to differentiate and to form pre-tubular
aggregates. WT1 expression level is increased in the pre-
tubular aggregate domain (Figure 1b). Fgf8 and Wnt4 are
expressed in pre-tubular aggregates and are required for
mesenchymal–epithelial transition to develop the renal
vesicle.17 On the basis of direct evidence from ChIP
experiments, β-catenin and LEF/TCF complexes together
with Six2 regulate Fgf8 and Wnt4 transcription in pre-tubular
aggregate.18 Interestingly, WT1 also binds to the cis-
regulatory regions of Fgf8 and Wnt4 and activates their
expression.11,19 Somatic deletion of Wt1 at E13.5 disrupts
MM epithelialization and results in the lack of nephrons at
birth.20 Taken together, WT1 controls MM differentiation
and mesenchymal–epithelial transition mainly by regulation
of Fgf8 and Wnt4, probably cooperating with β-catenin, LEF/
TCF, and Six2 complexes (Figure 2).
WT1 REGULATES PODOCYTE MATURATION AND
HOMEOSTASIS
After MM mesenchymal–epithelial transition, Wt1 expression
continues to increase along with the development of podocyte
progenitors and is later restricted to adult podocytes. Mature
podocytes consist of four morphologically distinct segments:
a cell body, major processes, secondary processes, and foot
processes (FPs). Between interdigitating FPs of neighboring
podocytes, a unique structure, the slit diaphragm (SD), is
formed. FPs are functionally defined by three membrane
domains: the apical membrane domain, the SD, and the basal
membrane domain that is attached to the glomerular basement
membrane. The integrity of podocytes and their interaction with
the glomerular basement membrane is crucial for maintenance
of the intact glomerular filtration barrier. Alteration of the
intercellular junctions and cytoskeletal structure of podocytes or
their detachment from the membrane results in the development
of albuminuria.21 Investigations in humans, mouse, and fish
have revealed a large number of gene products involved in
podocyte development and maintenance (Supplementary Table
S2 online). WT1 mutations leading to disruption of podocyte
development or maintenance are associated with glomerulopa-
thies in DDS, FS, and steroid-resistant nephrotic syndrome.
Podocyte-specificWt1 knockout mice display defects in podocyte
differentiation and lead to kidney failure and death within 24 h
after birth.12 Inducible adult podocyte Wt1 knockout mice show
FP effacement, proteinuria, and glomerulosclerosis, thus con-
firming the essential roles of Wt1 in podocyte maturation and
maintenance (Figure 3a).22,23 Recent ChIP-Seq and transcrip-
tome analyses have shed light on the WT1-controlled transcrip-
tion network in adult podocytes (Figure 3b).12,13
WT1 controls the expression of SD component encoding
genes
The SD is a specialized protein complex structure of podo-
cytes, which serves as a blood filtration unit and constitutes a
fundamental component of the glomerular filtration barrier.
The SD, as a specialized intercellular junction connecting
neighboring FPs, contains elements of tight, adherens, and
gap junctions. The SD is also considered as a complex
signaling hub for regulating the plasticity of podocyte FPs
and the loss of SD integrity leading to proteinuria.24
Interestingly, WT1 binds to the proximal promoters of many
genes encoding proteins that localize to the SD structure of
podocytes, such as Nphs1, Nphs2, Magi2, Ptpro, Kirrel, Plce1,
Cldn5, and Nck2.12,13 This supports the hypothesis that
sharing transcription factor binding sites conserved in
distance and orientation can help control the expression of
genes that act together in the same biological context.25
Notably, the expression of SD protein encoding genes is
controlled differentially by WT1 variants. Magi2 expression
depends on the WT1+KTS isoform, whereas Nphs1 and
Nphs2 expressions are regulated by the WT1−KTS isoform.26
WT1 controls the polarity of podocytes and cytoskeleton
arrangement
Apart from the SD structure, a complex cytoskeleton
underlies the delicate architecture of podocytes to build and
maintain their apicobasal and planer cell polarity. Interrup-
tion of cytoskeleton structure and loss of polarity are among
characteristic features of injured podocytes.27 For example,
loss of the actin cytoskeletal proteins, ACTN4, SYNPO, and
MYH9, results in autosomal recessive nephrotic syndromes.
In addition, mutation of actin regulatory protein, ARH-
GAP24, a RhoA-activated Rac1 GTPase-activating protein,
also causes early or adult onset nephrotic syndrome.
Podocyte-specific knockout of the polarity protein aPKC, a
central component of Par3-Par6-aPKC complex, in mice also
results in the nephrotic syndrome (Supplementary Table S2
online). WT1 binds the cis-regulatory elements of those genes
in ChIP-Seq experiments, indicating that WT1 controls the
polarity of podocytes and cytoskeleton arrangement.12,13
WT1 controls the cell-matrix adhesion of podocytes
Tight adherence of podocyte to the glomerular basement
membrane is another prerequisite for maintaining the
integrity of the glomerular filtration barrier due to its expo-
sure to permanent transcapillary filtration pressure. The
major cell-matrix adhesion receptor in podocytes is integrin
α3β1 connecting to laminin 521 in the glomerular basement
688 Kidney International (2015) 88, 684–690
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membrane.28 Mutations in ITGA3 and LAMB2 in human
patients or podocyte-specific knockout of Itgb1 and Lama5 in
mice result in FP effacement and proteinuria (Supplementary
Table S2 online). All the cis-regulatory regions of these genes
have WT1 binding signals, suggesting that WT1 controls the
cell-matrix adhesion of podocytes.12,13
WT1 and the concept of super-enhancers
By taking a closer look at the WT1 binding loci in the
podocyte-specific genes, it is apparent that, in many cases,
several WT1 binding sites localize to intragenic or intergenic
regions in the gene’s cis-regulatory domains, such as in
Synaptopodin and Magi2 (Figure 3c). Correlation analysis
with expression data from FACS-sorted podocytes suggests
that genes harboring multiple WT1 binding sites usually have
a higher expression level in podocytes than genes having no or
only one Wt1 binding sequence. The analysis of these
enhancer peaks shows a significant enrichment for MAFB,
Homeobox, Tcf-family, and Fox-class binding sites, indicating
that these factors may cooperate with WT1 to regulate
podocyte-specific gene expression.13 WT1 binds to its own
promoter, suggesting an auto-regulatory loop.11–13 WT1 also
regulates the expression of Mafb, Lmx1b, Foxc2, and Tcf21,
which are podocyte-specific transcription factors. Mutation
of each of them causes the loss of kidney function
(Supplementary Table 2 online). These findings are reminis-
cent of the concept of super-enhancers, which consist of
clusters of enhancers that are densely occupied by master
regulators and Mediator for enhancing the cell-specific gene
expression pattern.29 In light of this paradigm, the recent data
suggest that WT1 works together with Mafb, Lmx1b, FoxC2,
and Tcf21 to define podocyte identity as a master regulator by
activating the podocyte-specific super-enhancers, together
with Mediator.
CONCLUSION AND PERSPECTIVE
WT1 mutations result in a large spectrum of phenotypes,
either caused by dysfunction of kidney progenitors or
podocytes. Significant advances have recently been made in
the understanding of WT1 function in kidney biology and
kidney pathophysiology associated with WT1 mutations,
providing promising therapeutic applications. Recently,
application of in utero delivery of a pseudotyped rAAV 2/9
vector provides a possible avenue for the targeting of gene
therapies of WT1 mutation–related kidney diseases.30 In
addition, understanding the molecular mechanism of kidney
development has fostered the establishment of protocols for
the generation of mature kidney cell types and the three-
dimensional nephron-like structures from pluripotent cells.31
Transplantation of the de novo nephrons generated from stem
cells under a mouse kidney capsule could integrate the already
existing blood stream into the glomerulus, thus enhancing
potential treatment of kidney diseases.31 Although these
therapeutic directions point toward a translational relevance,
in addition, developing pharmacological agents can help
combat kidney disorders. A drug screening platform can be
established from reconstituted kidneys in vitro, derived
from pluripotent stem cells from WT1 mutant patients.
Simultaneously, a better understanding of the complex
WT1-dependent molecular mechanisms involved in podocyte
biology coupled with directed differentiation protocols will
assist in the generation of large quantities of pure podocytes,
thus, paving the way for novel clinical applications.
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